Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation

Journal of Immunology

Volumn 173, Issue 12, 2004, Pages 7531-7538

  Ariga, Miyako ^a   Neitzert, Barbara ^a   Nakae, Susumu ^a   Mottin, Genevieve ^b   Bertrand, Claude ^b   Pruniaux, Marie Pierre ^b   Jin, S L Catherine ^a   Conti, Marco ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CYCLIC AMP; ENDOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 2; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FLOW CYTOMETRY; IMMUNOPRECIPITATION; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LUNG INJURY; LUNG LAVAGE; LYMPHOCYTE; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 10344242415     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.12.7531     Document Type: Article

References (58)

1. Kammer, G. M. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9:222.
2. Skalhegg, B. S., B. F. Landmark, S. O. Doskeland, V. Hansson, T. Lea, and T. Jahnsen. 1992. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 267:15707.
3. Torphy, T. J. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157:351.
4. Tannenbaum, C. S., and T. A. Hamilton. 1989. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol. 142:1274.
5. Parhami, F., Z. T. Fang, A. M. Fogelman, A. Andalibi, M. C. Territo, and J. A. Berliner. 1993. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J. Clin. Invest. 92:471.
6. Fine, J. S., H. D. Byrnes, P. J. Zavodny, and R. W. Hipkin. 2001. Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis. Inflammation 25:61.
7. 3H]rolipram binding. Biochem. Pharmacol. 51:949.
8. Barnette, M. S., S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy. 1998. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284:420.
9. Nielson, C. P., R. E. Vestal, R. J. Sturm, and R. Heaslip. 1990. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86:801.
10. Bessler, H., R. Gilgal, M. Djaldetti, and I. Zahavi. 1986. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J. Leukocyte Biol. 40:747.
11. Au, B. T., M. M. Teixeira, P. D. Collins, and T. J. Williams. 1998. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br. J. Pharmacol. 123:1260.
12. Derian, C. K., R. J. Santulli, P. E. Rao, H. F. Solomon, and J. A. Barrett. 1995. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154:308.
13. Harvath, L., J. D. Robbins, A. A. Russell, and K. B. Seamon. 1991. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. J. Immunol. 146:224.
14. Torphy, T. J. 1994. β-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol. Sci. 15:370.
15. VanUffelen, B. E., B. M. de Koster, and J. G. Elferink. 1998. Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III. Biochem. Pharmacol. 56:1061.
16. Li, L., C. Yee, and J. A. Beavo. 1999. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848.
17. Glavas, N. A., C. Ostenson, J. B. Schaefer, V. Vasta, and J. A. Beavo. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA 98:6319.
18. Jin, S. L., and M. Conti. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA 99:7628.
19. Wang, P., P. Wu, K. M. Ohleth, R. W. Egan, and M. M. Billah. 1999. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. 56:170.
20. Seldon, P. M., and M. A. Giembycz. 2001. Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10. Br. J. Pharmacol. 134:58.
21. Conti, M., and S. L. Jin. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1.
22. 2-adrenoreceptor desensitization. J. Biol. Chem. 273:20575.
23. Engels, P., K. Fichtel, and H. Lubbert. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:291.
24. Houslay, M. D., M. Sullivan, and G. B. Bolger. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44:225.
25. Giembycz, M. A. 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59:193.
26. Gantner, F., H. Tenor, V. Gekeler, C. Schudt, A. Wendel, and A. Hatzelmann. 1997. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J. Allergy Clin. Immunol. 100:527.
27. Tenor, H., A. Hatzelmann, A. Wendel, and C. Schudt. 1995. Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate- dependent up-regulation in a human keratinocyte cell line (HaCaT). J. Invest. Dermatol. 105:70.
28. Howell, R. E., W. T. Muehsam, and W. J. Kinnier. 1990. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci. 46:563.
29. Souness, J. E., D. Aldous, and C. Sargent. 2000. Immumosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127.
30. Jin, S. L., F. J. Richard, W. P. Kuo, A. J. D'Ercole, and M. Conti. 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad. Sci. USA 96:11998.
31. Thompson, W. J., and M. M. Appleman. 1971. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311.
32. Devi, S., J. Laning, Y. Luo, and M. E. Dorf. 1995. Biologic activities of the β-chemokine TCA3 on neutrophils and macrophages. J. Immunol. 154:5376.
33. Campbell, J. J., E. F. Foxman, and E. C. Butcher. 1997. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur. J. Immunol. 27:2571.
34. Frevert, C. W., S. Huang, H. Danaee, J. D. Paulauskis, and L. Kobzik. 1995. Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. J. Immunol. 154:335.
35. 2-inhibitory effects in human neutrophils. Inflamm. Res. 49:600.
36. Teixeira, M. M., R. W. Gristwood, N. Cooper, and P. G. Hellewell. 1997. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18:164.
37. Tasken, K., and E. M. Aandahl. 2004. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 84:137.
38. Rivkin, I., and E. L. Becker. 1976. Effect of exogenous cyclic AMP and other adenine nucleotides on neutrophil chemotaxis and motility. Int. Arch. Allergy Appl. Immunol. 50:95.
39. Servant, G., O. D. Weiner, P. Herzmark, T. Balla, J. W. Sedat, and H. R. Bourne. 2000. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science 287:1037.
40. Laudanna, C., J. J. Campbell, and E. C. Butcher. 1997. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J. Biol. Chem. 272:24141.
41. 2 integrin avidity in neutrophils. J. Leukocyte Biol. 71:1042.
42. Tasken, K. A., P. Collas, W. A. Kemmner, O. Witczak, M. Conti, and K. Tasken. 2001. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J. Biol. Chem. 276:21999.
43. Barlic, J., J. D. Andrews, A. A. Kelvin, S. E. Bosinger, M. E. DeVries, L. Xu, T. Dobransky, R. D. Feldman, S. S. Ferguson, and D. J. Kelvin. 2000. Regulation of tyrosine kinase activation and granule release through β-arrestin by CXCRI. Nat. Immunol. 1:227.
44. Luttrell, L. M., and R. J. Lefkowitz. 2002. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115:455.
45. Fong, A. M., R. T. Premont, R. M. Richardson, Y. R. Yu, R. J. Lefkowitz, and D. D. Patel. 2002. Defective lymphocyte chemotaxis in β-arrestin2- and GRK6-deficient mice. Proc. Natl. Acad. Sci. USA 99:7478.
46. Perry, S. J., G. S. Baillie, T. A. Kohout, I. McPhee, M. M. Magiera, K. L. Ang, W. E. Miller, A. J. McLean, M. Conti, M. D. Houslay, et al. 2002. Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science 298:834.
47. i. Proc. Natl. Acad. Sci. USA 100:940.
48. Mizgerd, J. P., H. Kubo, G. J. Kutkoski, S. D. Bhagwan, K. Scharffetter-Kochanek, A. L. Beaudet, and C. M. Doerschuk. 1997. Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18-deficient mice. J. Exp. Med. 186:1357.
49. Hansen, G., S. Jin, D. T. Umetsu, and M. Conti. 2000. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. USA 97:6751.
50. Corbel, M., N. Germain, J. Lanchou, S. Molet, P. M. R. e Silva, M. A. Martins, E. Boichot, and V. Lagente. 2002. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-β release during acute lung injury in mice: the role of the balance between tumor necrosis factor-α and interleukin-10. J. Pharmacol. Exp. Ther. 301:258.
51. Goncalves de Moraes, V. L., M. Singer, B. B. Vargaftig, and M. Chignard. 1998. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. 123:631.
52. Trifilief, A., D. Wyss, C. Walker, L. Mazzoni, and R. Hersperger. 2002. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J. Pharmacol. Exp. Ther. 301:241.
53. Haddad, E. B., M. Birrell, K. McCluskie, A. Ling, S. E. Webber, M. L. Foster, and M. G. Belvisi. 2001. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br. J. Pharmacol. 132:1715.
54. Profita, M., G. Chiappara, F. Mirabella, R. Di Giorgi, L. Chimenti, G. Costanzo, L. Riccobono, V. Bellia, J. Bousquet, and A. M. Vignola. 2003. Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 58:573.
55. Haddad, J. J., S. C. Land, W. O. Tarnow-Mordi, M. Zembala, D. Kowalczyk, and R. Lauterbach. 2002. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide- mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300:559.
56. Dubravec, D. B., D. R. Spriggs, J. A. Mannick, and M. L. Rodrick. 1990. Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor α. Proc. Natl. Acad. Sci. USA 87:6758.
57. Ackerman, V., M. Marini, E. Vittori, A. Bellini, G. Vassali, and S. Mattoli. 1994. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients: relationship to atopic status, symptoms, and level of airway hyperresponsiveness. Chest 105:687.
58. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110:1045.